Brenda Gati Mirembe, MU-JHU
MU-JHUPresenter Of 2 Presentations
Symposia session
Introduction
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Symposia session
Conclusion
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Moderator Of 1 Session
Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
Biomedical prevention strategies – particularly PrEP – are highly efficacious, but their impact is greatest so far in men who have sex with men. Women are seemingly falling behind with prevention options; a common narrative still exists that PrEP works less well in women and that women do not take PrEP. Strikingly, the newest PrEP option (oral emtricitabine/tenofovir alafenamide) was recently approved with an indication that explicitly excludes women. Together, this begs the question: Are women losing out when it comes to biomedical HIV prevention?
Presenter Of 2 Presentations
Symposia session
Introduction
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Symposia session
Conclusion
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Moderator Of 1 Session
Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
Biomedical prevention strategies – particularly PrEP – are highly efficacious, but their impact is greatest so far in men who have sex with men. Women are seemingly falling behind with prevention options; a common narrative still exists that PrEP works less well in women and that women do not take PrEP. Strikingly, the newest PrEP option (oral emtricitabine/tenofovir alafenamide) was recently approved with an indication that explicitly excludes women. Together, this begs the question: Are women losing out when it comes to biomedical HIV prevention?
Presenter Of 2 Presentations
Symposia session
Conclusion
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Symposia session
Introduction
Session Name
Room
Symposia and bridging sessions On-Demand Channel
Moderator Of 1 Session
Symposia session
Room
Symposia and bridging sessions On-Demand Channel
Session Description
Biomedical prevention strategies – particularly PrEP – are highly efficacious, but their impact is greatest so far in men who have sex with men. Women are seemingly falling behind with prevention options; a common narrative still exists that PrEP works less well in women and that women do not take PrEP. Strikingly, the newest PrEP option (oral emtricitabine/tenofovir alafenamide) was recently approved with an indication that explicitly excludes women. Together, this begs the question: Are women losing out when it comes to biomedical HIV prevention?